Granted Patent
B2
US 12,528,818 · App. 19/196,683 · Granted Jan 20, 2026
Compositions and methods for inhibition of RAS
Inventors:
Bin Wang (Dallas, TX); Rui Xu (Dallas, TX); Eli Wallace (Loveland, CO); Zuhui Zhang (Millbrae, CA); David Michael Turner (Frederick, MD); Anna Elzbieta Maciag (Frederick, MD); Dhirendra Kumar Simanshu (Frederick, MD); Albert Hay Wah Chan (Frederick, MD); Tao Liao (Frederick, MD); Christopher John Brassard (Frederick, MD); Yue Yang (Foster City, CA); Paola Bisignano (San Francisco, CA); Felice Lightstone (Fremont, CA)
Assignees:
Leidos Biomedical Research, Inc.; Lawrence Livermore National Security, LLC; TheRas, Inc.
C07D487/10A61K31/517A61K31/551C07D409/04C07D409/14C07D413/14C07D417/04C07D417/14C07D471/08C07D471/10C07D487/04C07D519/00
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided herein are compounds, or salts, esters, tautomers, prodrugs, zwitterionic forms, or stereoisomers thereof, as well as pharmaceutical compositions comprising the same. Also provided herein are methods of using the same in modulating (e.g., inhibiting) KRAS (e.g., KRAS having a G12C mutation) and treating diseases or disorders such as cancers in subjects in need thereof.
Claims (23)
1 . A compound selected from:
or a pharmaceutically acceptable salt thereof.
2 . A compound having the structure:
or a pharmaceutically acceptable salt thereof.
3 . A compound having the structure:
or a pharmaceutically acceptable salt thereof.
4 . A compound having the structure:
or a pharmaceutically acceptable salt thereof.
5 . A compound of claim 1 , wherein the compound is selected from:
6 . The compound of claim 2 , wherein the compound is
7 . The compound of claim 3 , wherein the compound is
8 . The compound of claim 4 , wherein the compound is
9 . A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
10 . The pharmaceutical composition of claim 9 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
11 . The pharmaceutical composition of claim 9 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
12 . The pharmaceutical composition of claim 9 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
13 . A pharmaceutical composition comprising a compound of claim 5 .
14 . The pharmaceutical composition of claim 13 , wherein the compound is
15 . The pharmaceutical composition of claim 13 , wherein the compound is
16 . The pharmaceutical composition of claim 13 , wherein the compound is
Assignments (5)
CONFIRMATORY LICENSE
Recorded Jan 13, 2026
From: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC
To: NNSA
Reel/Frame 074331/0241 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 9, 2025
From: TURNER, DAVID MICHAEL; MACIAG, ANNA ELZBIETA; SIMANSHU, DHIRENDRA KUMAR; CHAN, ALBERT HAY WAH; LIAO, TAO; BRASSARD, CHRISTOPHER JOHN
To: LEIDOS BIOMEDICAL RESEARCH, INC.
Reel/Frame 071364/0191 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 9, 2025
From: YANG, YUE; BISIGNANO, PAOLA; LIGHTSTONE, FELICE
To: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC
Reel/Frame 071364/0325 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 9, 2025
From: WANG, BIN; XU, RUI; WALLACE, ELI; ZHANG, ZUHUI
To: BRIDGEBIO SERVICES, INC.
Reel/Frame 071364/0411 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 9, 2025
From: BRIDGEBIO SERVICES, INC.
To: THERAS, INC.
Reel/Frame 071364/0462 →
Continuity (4)
Continuation
18291432
Provisional Application
63329237
· Apr 8, 2022
Provisional Application
63225407
· Jul 23, 2021
References Cited (92)
US 9840516B2
· Li et al.
· 2017
[cited by applicant]
US 20230174526A1
· Wan et al.
· 2023
[cited by applicant]
US 20230365563A1
· Zhang et al.
· 2023
[cited by applicant]
US 20240109893A1
· Tian et al.
· 2024
[cited by applicant]
US 20240300964A1
· Wang et al.
· 2024
[cited by applicant]
US 20250154133A1
· Li et al.
· 2025
[cited by applicant]
CN 112110918A
· 2020
[cited by applicant]
CN 113754653A
· 2021
[cited by applicant]
CN 113999226A
· 2022
[cited by applicant]
CN 115433179A
· 2022
[cited by applicant]
WO WO2013155223A1
· 2013
[cited by applicant]
WO WO2014152588A1
· 2014
[cited by applicant]
WO WO2015054572A1
· 2015
[cited by applicant]
WO WO2016044772A1
· 2016
[cited by applicant]
WO WO2016049568A1
· 2016
[cited by applicant]
WO WO2016164675A1
· 2016
[cited by applicant]
WO WO2017087528A1
· 2017
[cited by applicant]
WO WO2017100546A1
· 2017
[cited by applicant]
WO WO2017172979A1
· 2017
[cited by applicant]
WO WO2018218069A1
· 2018
[cited by applicant]
WO WO2018218070A2
· 2018
[cited by applicant]
WO WO2020081282A1
· 2020
[cited by applicant]
WO WO2020097537A2
· 2020
[cited by applicant]
WO WO2021108683A1
· 2021
[cited by applicant]
WO WO2021129820A1
· 2021
[cited by applicant]
WO WO2021218110A1
· 2021
[cited by applicant]
WO WO2022002018A1
· 2022
[cited by applicant]
WO WO2022002102A1
· 2022
[cited by applicant]
WO WO2022047260A1
· 2022
[cited by applicant]
WO WO2022061251A1
· 2022
[cited by applicant]
WO WO2022068921A1
· 2022
[cited by applicant]
WO WO2022083616A1
· 2022
[cited by applicant]
WO WO2022093856A1
· 2022
[cited by applicant]
WO WO2022105855A1
· 2022
[cited by applicant]
WO WO2022119748A1
· 2022
[cited by applicant]
WO WO2022135470A1
· 2022
[cited by applicant]
WO WO2022148422A1
· 2022
[cited by applicant]
WO WO2022156792A1
· 2022
[cited by applicant]
WO WO2022177917A2
· 2022
[cited by examiner]
WO WO2022251576A1
· 2022
[cited by applicant]
WO WO2022261154A1
· 2022
[cited by applicant]
WO WO2023004102A2
· 2023
[cited by applicant]
WO WO2023018699A1
· 2023
[cited by applicant]
WO WO2023133181A1
· 2023
[cited by applicant]
WO WO2023133183A1
· 2023
[cited by applicant]
WO WO2023141300A1
· 2023
[cited by applicant]
WO WO2023150284A2
· 2023
[cited by applicant]
WO WO2023179703A1
· 2023
[cited by applicant]
WO WO2023215801A1
· 2023
[cited by applicant]
WO WO2023225252A1
· 2023
[cited by applicant]
WO WO2024030633A1
· 2024
[cited by applicant]
WO WO2024030647A1
· 2024
[cited by applicant]
WO WO2024158778A1
· 2024
[cited by applicant]
WO WO2025117828A1
· 2025
[cited by applicant]
Garske, A. L. et al., Chemical genetic strategy for targeting protein kinases based on covalent complementarity, PNAS, 108(37):15046-15052 (2011).
[cited by applicant]
International Search Report for PCT/US2022/037992, filed Jul. 22, 2022, 8 pages, (mailed Jan. 23, 2023).
[cited by applicant]
Invitation to Pay Additional Fees for PCT/US2022/037992, filed Jul. 22, 2022, 13 pages, (mailed Dec. 1, 2022).
[cited by applicant]
Written Opinion for PCT/US2022/037992, filed Jul. 22, 2022, 10 pages, (mailed Jan. 23, 2023).
[cited by applicant]
Ebright, R. Y. et al., Response and Resistance to RAS Inhibition in Cancer, Cancer Discov., 15(7):1325-1349 (2025).
[cited by applicant]
International Search Report for PCT/US2022/016487, 9 pages (mailed Aug. 19, 2022).
[cited by applicant]
International Search Report for PCT/US2023/010172, 4 pages (mailed May 11, 2023).
[cited by applicant]
International Search Report for PCT/US2023/010176, 4 pages (mailed May 11, 2023).
[cited by applicant]
International Search Report for PCT/US2023/029520, 7 pages (mailed Dec. 21, 2023).
[cited by applicant]
International Search Report for PCT/US2023/029537, 5 pages (mailed Nov. 23, 2023).
[cited by applicant]
International Search Report for PCT/US2024/012559, 11 pages (mailed Jun. 21, 2024).
[cited by applicant]
International Search Report for PCT/US2024/057867, 4 pages (mailed Mar. 5, 2025).
[cited by applicant]
Maciag, A. E. et al. Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C, Cancer Discov., 579-594 (2025).
[cited by applicant]
McGregor, L. M. et al. Expanding the Scope of Electrophiles Capable of Targeting K-Ras Oncogenes, Biochem., 56(25):3178-3183 (2017).
[cited by applicant]
Mei, R. et al., Oxazolinyl-Assisted C-H Amidation by Cobalt (III) Catalysis, ACS Catalysis, 6(2):793-797 (2016).
[cited by applicant]
Ostrem, J. M. et al., K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions, Nature, 503(7477):548-551 (2013).
[cited by applicant]
Rosell, R. et al., KRAS G12C-mutant driven non-small cell lung cancer (NSCLC), Crit. Rev. Oncol. Hem., 195(104228):1-19 (2024).
[cited by applicant]
Uras, I. Z. et al., Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future, Int. J. Mol. Sci., 21:4325-4355 (2020).
[cited by applicant]
Wouters, R. et al., A Scaffold-Hopping Strategy toward the Identification of Inhibitors of Cyclin G Associated Kinase, ChemMedChem, 14(2):237-254 (2018).
[cited by applicant]
Written Opinion for PCT/US2022/016487, 25 pages (mailed Aug. 19, 2022).
[cited by applicant]
Written Opinion for PCT/US2023/010172, filed Jan. 5, 2023, 6 pages (mailed May 11, 2023).
[cited by applicant]
Written Opinion for PCT/US2023/010176, 6 pages (mailed May 11, 2023).
[cited by applicant]
Written Opinion for PCT/US2023/029520, 14 pages (mailed Dec. 21, 2023).
[cited by applicant]
Written Opinion for PCT/US2023/029537, 9 pages (mailed Nov. 23, 2023).
[cited by applicant]
Written Opinion for PCT/US2024/012559, 12 pages (mailed Jun. 21, 2024).
[cited by applicant]
Written Opinion for PCT/US2024/057867, 13 pages (mailed Mar. 5, 2025).
[cited by applicant]
Xu, J. et al., Atroposelective Negishi Coupling Optimization Guided by Multivariate Linear Regression Analysis: Asymmetric Synthesis of KRAS G12C Covalent Inhibitor GDC-6036, Jrnl. Ameri. Chem. Soc., 144(45):20955-20963…
[cited by applicant]
Zhou, Z. and Westover, K. D., Beyond First-Generation KRAS Inhibitors: BBO-8520 Tests the Dual Mechanism Hypothesis, Cancer Discov., 455-457 (2025).
[cited by applicant]